New drug combo shows promise against childhood cancer
NCT ID NCT07549321
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether adding an antibody drug called hu14.18K322A to standard chemotherapy helps children with high-risk neuroblastoma, a rare but aggressive childhood cancer. About 144 children and teens aged 18 months to 18 years will receive the combination over up to 12 cycles. Researchers will measure how many patients' tumors shrink or disappear, and track survival over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hu14.18K322A (daretabart) combined with temozolomide and irinotecan
What this could lead to
If successful, this combination could improve response rates and survival for children with high-risk neuroblastoma, potentially leading to a new standard treatment.
What could go wrong
This is an early-to-mid-stage trial with only 144 participants, so results may not apply to all patients. The treatment involves chemotherapy, which carries significant side effects like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado Anschutz Medical
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Children's Hospital at Montefiore
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Minnesota Masonic Children's Hospital
RECRUITINGMinneapolis, Minnesota, 55454, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••